BioAdaptives Inc (BDPT)

[powerbattles]

Why isn't the company making money yet?

Approximately three years ago, CEO Dr. Edward E. Jacobs assumed leadership of the company and has since been dedicated to the development of new drugs. It is common knowledge that the process of drug development in the biotech industry often takes between 5 to 15 years, resulting in limited current revenue for most companies.
Many biotech companies list on the OTC market, develop products for many years, and still show nothing to market. However, BDPT is different. They have indicated Proven-Trusted-Success. In just a few years, they have successfully brought many products to market, and recently, they listed full products on Amazon.

https://www.amazon.com/s?k=BIOADAPTIVES&language=en_US&linkCode=sl2&linkId=90062364c52c856ed6f0c509d276cb7f&tag=eddiesthisand-20&ref=as_li_ss_tl

The reason people are investing in this biotech stock is not solely based on its current offerings, but rather the immense potential it holds. With a series of anticipated news and press releases during the month March and April, along with the addition of new board members, licensing agreements for innovative products with patents valued at over $750 million, and upcoming spin-off plans, there is a significant buzz around the company. Additionally, the company's connection to artificial intelligence further adds to its allure.

Furthermore, if you view the bio of the CEO he is the INVENTOR and The DOCTOR graduated the best Ivy League school in the world.
https://www.shopbioadaptives.com/blogs/news/cv

CEO Dr. Edward E. Jacobs
Patents by Inventor Edward E. Jacobs, Jr.
https://patents.justia.com/inventor/edward-e-jacobs-jr
https://podcasts.apple.com/be/podcast/natural-green-living/id1523571157?l=nl

CEO Dr. Edward E. Jacobs Graduated the best Ivy League school Leagues. Graduate of Harvard Medical school and Princeton University. IVY Legue School ranked

1 - HARVARD
2 - PRINCETON

https://prepexpert.com/ivy-league-school-rankings/#:~:text=Ivy%20League%20Schools%3A%20Ranked%201%201.%20Harvard%20Harvard,7%207.%20Dartmouth%20...%208%208.%20Cornell%20

In all my years of research, I have never seen a case like this before. The CEO and directors are genuinely focused on building the business. It's impressive that they have waived their compensation, demonstrating their commitment to retaining earnings and not simply seeking to scam our money.

Item 11. Executive Compensation

We have employment agreements with our Chief Executive Officer, President and Chief Financial Officer, each of whom was to be compensated by stock grants accrued monthly based on current share prices or block grants during the period ended December 31, 2022. In consideration of the Company’s financial performance and lack of liquidity during this period, each of our officers waived compensation and we adjusted compensation accordingly.

On top of everything, we have here. Bruce Colclasure is the President of BioAdaptives’ Livestock Impact Division. The company's pending spin-off Livestock Impact Division.
Bruce Colclasure, a National Cutting Horse Association champion who owns and operates the Flying C Bar Ranch and is the breeder and trainer of over 80 NCHA champion cutting horses. Winner and owner of numerous champion horses1. He is also a judge for the National Cutting Horse Association (NCHA)

https://www.livestockimpact.com/

https://unitedstatescutting.com/hof.php

He is also the Flying C Bar Ranch Owner. https://flyingcbar.myshopify.com/

Flying C Bar Ranch Performance Horses
https://www.facebook.com/flyingcbarranch1/

FLYING C BAR RANCH VIDEO. This is a huge facility.

Finally, this is an incredibly rare opportunity, and it's unbelievable that virtually nobody knows what's happening here. I mean, they have a double-blind Human Clinical Trial, and even the IRB gave their approval. Developing a product and getting approval for a clinical trial can take many years, and the potential market value is in the multibillion-dollar range. It's insane that we're still trading below one penny. This is beyond crazy!

Double blind placebo controlled study showed increased in circulating primitive cells regarding product cell Rejuven.

https://www.shopbioadaptives.com/pages/primicell-study

A double-blind human clinical trial is a type of research study used to test the safety and effectiveness of a new medical intervention, such as a drug or treatment. In a double-blind trial, both the participants and the researchers involved are unaware of which participants are receiving the actual treatment and which are receiving a placebo (inactive substance). This is done to eliminate bias and ensure the results are objective and reliable.

An Institutional Review Board (IRB) is an independent committee that reviews and approves the design and methods of human research studies to ensure the protection of participants' rights, safety, and well-being. Before a clinical trial can begin, it must be approved by the IRB to ensure that ethical principles are followed, and the study meets all necessary regulatory requirements. The IRB ensures that risks are minimized, and potential benefits are carefully considered before allowing the study to proceed.

My Previous DD
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=172294194